Bio-Rad Laboratories anti-pertuzumab antibodies
Bio-Rad Laboratories has introduced four inhibitory antibodies that are highly specific to pertuzumab (Perjeta). The ready-made antibodies inhibit the binding of the drug to its target, human epidermal growth factor 2 (HER2), enabling researchers to develop selective and sensitive assays for bioanalysis and drug monitoring of pertuzumab and its biosimilars.
Pertuzumab is a targeted cancer drug that binds to the HER2 protein, which is overexpressed in HER2-positive cancers, preventing cell growth and proliferation. The range of anti-pertuzumab antibodies includes monovalent Fab format antibodies suitable for the development of a pharmacokinetic bridging ELISA to measure free drug, as well as fully human IgG1 antibodies with varying levels of affinity, which can be used as a surrogate positive control or reference standard in an anti-drug antibody assay.
The antibodies are generated using the Human Combinatorial Antibody Libraries (HuCAL) and CysDisplay, a method of phage display, along with guided selection methods to obtain highly targeted reagents. The recombinant production method is designed to ensure a consistent and secure supply. The antibodies are approved for in vitro research purposes and for commercial services providing in vitro testing to support preclinical and clinical drug development.
Phone: 02 9914 2800
RevMAb Biosciences histone family protein monoclonal antibodies
RevMAb Biosciences offers a wide range of recombinant monoclonal antibodies against histone...
Biosensis MAP2 antibodies
Biosensis's validated MAP2 antibodies are designed to help users identify MAP2, whether they...
Bio-Rad Laboratories Celselect Slides validated antibodies for rare cell and CTC enumeration
The antibodies are specific to CTC surface markers to enable the sensitive and specific...